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Abstract
Background/Aim. High sera reactivity with a peptide derived
from human immunodeficiency virus HIV-1 envelope protein
gp120, NTM1, correlate with non-progressive HIV-1 infection
and also may have protective role in breast and prostate cancer.
We also detected a low NTM1 reactive antibodies titer in
healthy HIV negative sera and showed that antibody levels can
be significantly increased with vigorous physical activity. How-
ever, the immune system seems to be unresponsive or tolerant
to this peptide, implicating that the NTM1 sequence encom-
passes or overlaps a certain innate immune epitope. The aim of
this study was to present evidences that NTM1 – binding anti-
bodies – are components of innate immune humoral response,
by confirming their presence in sera of newborn babies. For
this purpose we collected a set of 225 innate antigen sequences
reported in the literature and screened it for candidate antigens
with the highest sequence and spectral similarity to NTM1 de-
rived from HIV-1 gp120. Methods. Sera from 18 newborns
were tested using ELISA, with peptide NTM1. Sequences from
innate antigen database were aligned by an EMBOSS Water
bioinformatics tool. Results. We identified NTM1 reactive an-
tibodies in sera of HIV negative newborn babies. Further, in
order to identify which of already known innate antigens are
the most similar to NTM1 peptide we screened innate immune
antigen sequence database collected from the literature. This
screening revealed that the most similar sequence are ribonu-
cleoproteins RO60, in addition to previously identified N-
terminus of vasoactive intestinal peptide. Conclusion. The re-
sults of this study confirm the hypothesis that NTM1 recog-
nizing antibodies are a part of humoral innate immune re-
sponse. Further, computational similarity screening revealed a
vasoactive intestinal peptide and RO60 as the most similar se-
quences and the strongest candidate antigens. In the light of the
presented results, it is appealing that testing blood reactivity at
birth, with specific innate antigens, particularly a vasoactive in-
testinal peptide, can reveal the potential to develop or boost
protective immune response in breast and prostate cancer and
HIV infection later in life.
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Apstrakt
Uvod/Cilj. Visoka reaktivnost seruma na peptid NTM1,
poreklom iz proteina omota?a gp120 virusa humane imu-
nodeficijencije, HIV-1, koreliše sa neprogresivnom HIV-1
infekcijom, a, tako?e, može imati zaštitnu ulogu u kanceru
dojke i prostate. Nedavno smo detektovali nizak titar anti-
tela reaktivnih na NTM1 i u zdravim HIV-negativnim se-
rumima i pokazali smo da se nivo ovih antitela može zna-
?ajno pove?ati energi?nom fizi?kom aktivnoš?u. Me?utim,
postoje dokazi da je ovaj peptid neimunogen ili da je nevid-
ljiv za imuni sistem ?oveka, ?ime se sugeriše da NTM1 sek-
venca obuhvata ili se preklapa sa odre?enim epitopom uro-
?ene imunosti. Cilj ove studije bio je da se dokumentuje da
su vezivna antitela, NTMI, sastavni delovi uro?enog humo-
ralnog imunog odgovora potv?ivanjem njihovog prisustva u
serumu novoro?en?adi. U tu svrhu, sakupili smo ukupno
225 uro?enih sekvenci antigena prikazanih u literaturi i testi-
rali ih za kandidate antigena sa najve?om sli?noš?u sekvence
i spektra NTM1 nastalih iz HIV-1 gp120. Metode. Serumi
18 novoro?en?adi testirani su ELISA probama sa NTM1
peptidom vezanim za plo?u. Poravnavanje sekvenci uro?e-
nih antigena vršeno je bioinformati?kim alatom EMBOSS
Water. Rezultati. U serumima HIV negativnih novoro?en-
?adi identifikovali smo antitela reaktivna na NTM1. Dalje,
da bi utvrdili koji od ve? poznatih antigena uro?ene imuno-
sti je najsli?niji peptidu NTM1, pretražili smo bazu sekvenci
antigena uro?ene imunosti formirane na osnovu literaturih
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podataka. Ovo pretraživanje pokazalo je da, pored predho-
dno identifikovanog N-terminusa vazoaktivnog intestinal-
nog peptida, najsli?nija je NTM1 peptidu sekvenca ribonu-
kleoproteina RO60. Zaklju?ak. Ovom studijom potvrdili
smo hipotezu da su antitela koja prepoznaju NTM1 deo
uro?enog humoralnog imunog odgovora. Dalje, kompjuter-
skim pretraživanjem sli?nosti utvrdili smo da su vazoaktivni
intestinalni peptid i RO60 sekvence najsli?nije NTM1 i, ta-
ko, najja?i kandidati za antigene. U svetlu predstavljenih re-
zultata, privla?na je ideja da testiranje reaktivnosti krvi sa
specifi?nim uro?enim antigenima, pre svega vazoaktivnim
intestinalnim peptidom na ro?enju, može otkriti potencijal
za razvoj protektivnog imunog odgovora kasnije u životu i
to ne samo za odre?ene autoimune bolesti, ve? i za kancer
dojke i prostate, kao i HIV infekcije.
Klju?ne re?i:
imunitet, prirodni; novoro?en?e; novoro?en?e,
prevremeno; antitela; vazoaktivni intestinalni peptid;
protein omota?a gp120 virusa hiv.
Introduction
In spite tremendous progress that has been made by in-
troducing highly active antiretroviral therapy (HAART) in in-
hibiting HIV-1 virus through disrupting reverse transcription,
integration or proteolytic processing of viral proteins, some
important problems as persistent viral reservoirs, drug resis-
tance and toxicities still remain. HAART can effectively keep
the viral replication at an undetectable level, prolonging the
life expectancy of the infected and reducing the viral transmis-
sion. However, several host and virus factors can slow down
and block the disease progression 1–4 and also, various immu-
nological factors 5, 6 might play an important role. NTM1 pep-
tide, derived from the C-terminus of the second conserved re-
gion of HIV-1 envelope protein gp120, and anti-NTM1 anti-
bodies have been suggested to be important in controlling HIV
disease. These antibodies have been significantly prevalent in
sera of long-term nonprogressors (LTNP), the HIV positives
that are capable of keeping viral load bellow 10 000 copies/mL
without any retroviral therapy for more than 10 years. The
same is observed in patients in asymptomatic phase of the
HIV-1 disease 7. NTM1 binding antibodies are reported in a
small number of healthy individuals and extremely high titer
values are detected in elite athletes 8. Although the immune
system seems to be unresponsive or tolerant to this peptide 9–11,
the titer NTM1 recognizing antibodies can be increased by
continuous and vigorous exercising 12. Taken together these
data implicate that NTM1 peptide encompasses or overlaps the
innate immune epitope sequence involved in cellular pathway
activated by physical activity. Based on the sequence similar-
ity and in vitro cross-reactivity we previously hypothesized
that the candidate binding antigen for these was vasoactive
intestinal peptide (VIP), the pleiotropic extracellular molecule
important in many physiologic functions, including glucose
homeostasis, neuroprotection, memory, gut function, modula-
tion of the immune system and circadian function. Due to its
important immunomodulatory and neuromodulatory activities,
circulating levels of VIP are under tight control. Natural anti-
VIP autoantibodies are potent modifiers of its biological ac-
tions and important regulators of its circulating level 13–17.
Natural autoantibodies (NAbs) are an important compo-
nent of the immune system, existing in all vertebrates and dem-
onstrating a non-pathogenic anti-self reactivity 18. NAbs are re-
active with only a restricted and specific set of proteins 19. The
function of these antibodies, although not fully elucidated, is to
provide early innate immune protection against certain patho-
gens, as well as the removal of possible autoantigens through
scavenging dead or apoptotic cellular debris through the lifetime
(for review see Lutz et al. 20). In general, mediators of innate
humoral immunity are low-affinity polyreactive antibodies with
an ability to bind to diverse, similar epitopes.
The aim of this study was to present evidences that
NTM1-binding antibodies are components of innate immune
humoral response, by confirming their presence in sera of
newborn babies. For this purpose we collected a set of 225
innate antigen sequences reported in the literature and
screened it for candidate antigens with the highest sequence
and spectral similarity to NTM1 derived from HIV-1 gp120.
Computational similarity screening revealed VIP and a ribo-
nucleoprotein, RO60, as the most similar sequences and the
strongest candidate antigens, although other highly similar
sequences were also identified. These results imply that
testing blood reactivity with specific innate antigens at birth
can reveal potential to develop or boost protective immune
response in breast and prostate cancer and HIV infection.
Methods
Sequences
The HIV1 gp120 NTM1 sequence was as in paper of
Djordjevic et al. 21 Innate immune antigen sequences are
listed in Addendum 1.
Sequence alignments
Sequence alignments are calculated by an EMBOSS
Water, a tool that uses the Smith-Waterman algorithm to cal-
culate the local alignment of two sequences 22. Sequences
with scores higher than 20 (scores were from 7 to 23) are
selected as candidate antigens.
Human subjects
Sera were collected from 9 preterm and 9 term new-
borns within the first 7 days after birth. The preterm infants
were born between the weeks 27–34 of gestation, with the
weight 950–2,200 g. The term newborns were born after 37
weeks of gestation, with the weight more than 2,500 g. After
centrifugation, sera were collected and stored at -20?C. The
sample material used in this study was what remained of se-
rum used for standard biochemical testing. Blood specimens
were not collected specifically for these experiments. The
study was approved by the Ethics Committee of the Institute
for Neonatology, Belgrade, Republic of Serbia.
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ELISA
ELISA was performed with peptide (NTM1)4-SOC4 by
the following procedure: polystyrene microtiter plates (Gre-
iner, Germany) were incubated overnight at 4°C with 100 ?l
of peptides (1.25 ?g/well) diluted in carbonate buffer, pH
9.6. Plates were washed with phosphate-buffered saline
(PBS)–0.05% Tween and non-specific sites were blocked
with 200 ?l PBS containing 5% bovine serum albumin
(BSA) for 2 h at room temperature. After 6 washings, serum
specimens were added to the wells (100 ?l /well). Sera were
diluted 1 : 20 in 5% BSA in PBS. Plates were incubated for
4h at room temperature. After 6 washings with PBS–0.05%
Tween, 100 ?l of goat anti-human IgM alkaline phosphatase-
conjugated antibodies (Sigma), diluted 1 : 50 were added and
the plates were incubated for 30 minutes at room tempera-
ture. After 6 washings, p-nitrophenyl phosphate (pNPP) sub-
strate was added and the absorbance optical density (OD)
measured at 405–620 nm after 15 minutes. Each sample was
tested twice. As a control we used antigen from Serion
ELISA classic Cytomegalovirus IgM (Institute Virion\Serion
GmbH).
Statistical analysis
The significance of the differences in O.D. values for
preterm and term infants was calculated by Student's t-test,
as the sample sizes were relatively small. The 2 groups were
unpaired with uneven variance and therefore they were con-
sidered as part of a two-tailed, heteroscedastic matrix.
Results
In order to show that NTM1 binding antibodies are in-
nate natural self-binding antibodies we determined their
presence in sera of HIV-1 negative neonates. Our previous
studies showed the presence of NTM1 antibodies of IgG
subclass in HIV positive LTNPs, as well as in elite athletes
and in small percentage of healthy HIV- adult popula-
tion 7, 23, but here NTM1 binding of IgM subclass of anti-
bodies specific to neonatal population were measured. Ma-
ternal antibodies of IgG subclass actively transfer across the
placenta and therefore can be related to her adaptive immune
response 24. Reactivity of sera in a small cohort of 18 HIV-1
negative new born babies (Table 1) was determined by the
ELISA immunoassay (Figure 1). Statistical analysis revealed
that this reactivity in sera from preterm neonates was signifi-
cantly higher in comparison with the reactivity of term neo-




























Fig. 1 – ELISA results of sera reactivity in the preterm
and the term neonates. Antibodies recognizing peptide
NTM1 were significantly more prevalent in serum samples
from the preterm neonates compared to the term neonates
(p < 0.001).
In search for innate epitopes similar to NTM1 we screened
literature data and identified 225 protein sequences reported to
encompass innate immune epitopes (Addendum 1) 20, 25–47. Con-
sidering the ability of natural antibodies to bind to diverse epi-
topes we selected the set candidate antigens as described in
Methods section (Table 2).
Discussion
Certain types of autoreactive immune cells and anti-
bodies are common in healthy individuals and play an im-
portant role in body homeostasis. Several functions have
been assigned to NAbs: neutralization of microbes and mi-
crobial toxins as natural first-line defence against infection,
removal of senescent/altered self molecules and cells and
immunomodulation and immunosignaling. New and unex-
pected insights into the functional roles of NAbs are still
emerging, especially regarding their protective functions.
NAbs are encoded by V(D)J genes in germline configuration
and belong to IgG, IgM and IgA subclasses.
Several studies which investigated humoral immune re-
sponse associated with the control of HIV-1 disease progres-
sion showed that the antibodies recognizing the peptide derived
from C-terminus of the second conserved region of HIV-1
gp120, NTM1, correlate with non-progressive HIV-1 infection.
Recently, the potential protective role of NTM1 antibodies has
also been shown in breast and prostate cancer patients. Due to
the fact that the peptide NTM1 is not immunogenic in
Table 1
Characteristics of infants at birth and the mean NTM1 ELISA absorbance values
Characteristics of infants Preterm(n = 9)
Term
(n = 9)
Gestational age at birth (weeks) < 34 > 37
Birth weight (grams) < 2500 > 2500
Sampling days < 7 < 7
Absorbance values for NTM antigen, ? ± SD 0.517 ± 0.107 0.287 ± 0.128
Absorbance values for control antigens, ? ± SD 0.120 ± 0.022 0.106 ± 0.009
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Table 2
Candidate antigens for NTM1 natural autoantibodies
Protein name AC No Score Pairwise sequence alignment
VIP P01282 23 NTM1 1 FTDN 4
||||
VIP_HUMAN 130 FTDN 133
RO60 ribonucleoprotein P10155 23 NTM1 1 FTDN 4
||||
RO60-HUMAN 467 FTDN 470
ATP synthase subunit alpha P25705 22 NTM1 1 FTDNAK 6
|.||.|
ATPA_HUMAN 300 FRDNGK 305
Histone H2A 2C Q16777 21 NTM1 3 DNAKT 7
||.||
H2A2C_HUMAN 73 DNKKT 77
Serum albumin P02768 21 NTM1 1 FTDNAKT 7
|.||.:|
ALBU_HUMAN 151 FHDNEET 157
Hsp70 P08107 21 NTM1 1 FTDNAKTI 8
|||..:.|
HSP71_HUMAN 44 FTDTERLI 51
Hsp71 P11142 21 NTM1 1 FTDNAKTI 8
|||..:.|
HSP7C_HUMAN 44 FTDTERLI 51
Myeloperoxidase P05164 21 NTM1 1 FTDNAKTI 8
|.||.:.:
PERM_HUMAN 369 FQDNGRAL 376
Fibronectin P02751 21 NTM1 1 FTDNAKT 7
||.|.:|
FINC_HUMAN 364 FTYNGRT 370
Thyroglobulin P01266 21 NTM1 1 FTDNAKTI 8
||.|.|.:
THYG_HUMAN 460 FTTNPKRL 467
           VIP – vasoactive intestinal peptide.
humans, it has been suggested that the antibodies recognizing
this peptide represent natural autoantibodies. Thus, we have
confirmed this hypothesis by detecting NTM1 antibodies in
newborn babies. Sera samples of a small cohort of 18 new-
borns not older than 7 days tested in ELISA experiments
showed a significant binding to NTM1 peptide. The differ-
ence between preterm and term serum titers are in line with
already observed major differences of functional immune
components between these two categories of neonates as re-
viewed in Sharma et al. 48. This may be explained by specific
innate immune defense pathways in protecting preterm in-
fants against infection, or by deregulated innate immune re-
sponses which play a major role in the etiology of certain
preterm neonatal complications later in life. Further, assum-
ing that NTM1 recognizing antibodies belong to the majority
of NAbs displaying rather low affinity and polyreactivity for
a range of ligands 49 we scanned the set of innate antigen se-
quences in order to identify those that are most similar to
NTM1. The collection of the 225 tested protein sequences
from literature data represents significant, but far from ex-
haustive list of innate immune antigens (Addendum 1). Based
on this inquiry we selected 10 most similar sequences as po-
tential binding antigens for NTM1 recognizing antibodies (Ta-
ble 2). The two prominent candidate antigens which show the
highest similarity score to NTM1 are extracellular VIP, whose
sera titer is tightly regulated by NAbs and RO60, which is an
antigen for anti-RO60 antibodies involved in the clearance of
apoptic debris 50. These findings are in perfect agreement with
major functional roles attributed to the natural IgM antibodies
in the maintenance of tissue homeostasis and immune regula-
tion 51–53. However, we suggest that more probably VIP serves
as the most important self-binding molecule for these anti-
bodies for the following reasons: it was identified as one of the
most important nodes in IgM antigen network conserved in
both, mothers and babies 54, NTM recognizing IgG antibodies
are cross-reactive with VIP in sera of HIV positives and in
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healthy adults 55, and the levels of circulating VIP in newborns
are significantly prevalent in preterm neonates compared to
term born babies 56 which could explain the statistically sig-
nificant prevalence of NTM1 recognizing antibodies (p <
0.001) in our study.
Conclusion
The information about the presence of NTM1 recog-
nizing natural antibodies at birth may be of significant im-
portance later in life due to the fact that these antibodies
might have protective roles in HIV-1 disease and in breast or
prostate cancer. Previous findings that these NAbs are re-
tained throughout life with potential of sera titer to be sig-
nificantly increased by physical exercise emphasize the need
for future exploration of NTM1 recognizing antibodies as
personalized therapeutic strategy based on the natural anti-
bodies repertoire. In the light of the presented results, it is
appealing that testing blood reactivity at birth, with specific
innate antigens, particularly vasoactive intestinal pephole
(VIP), can reveal the potential to develop or boost protective
immune response against certain life threatening diseases.
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Addendum 1
Innate immune antigen sequences
Protein name SwissProt ID Reference
Alpha-2-macroglobulin precursor - Homo sapiens (Human) [P01023] 24
Acetylcholinesterase precursor - Homo sapiens (Human) [P22303] 24
Serum albumin precursor - Homo sapiens (Human) [P02768] 24
Fructose-bisphosphate aldolase A - Homo sapiens (Human) [P04075] 24
Fructose-bisphosphate aldolase B - Homo sapiens (Human) [P05062] 24
Fructose-bisphosphate aldolase C - Homo sapiens (Human) [P09972] 24
Amyloid beta A4 protein-Homo sapiens (Human) [P05067] 25
Anion exchange protein 3-Homo sapiens (Human) [P48751] 26
Atrial natriuretic factor precursor - Homo sapiens (Human) [P01160] 24
Natriuretic peptides B precursor [Contains: Gamma-brain natriuretic peptide; Brain natriuretic
peptide 32 - Homo sapiens (Human) [P16860] 24
Annexin A10 - Homo sapiens (Human) [Q9UJ72] 24
Annexin A11 - Homo sapiens (Human) [P50995] 24
Annexin A13 - Homo sapiens (Human) [P27216] 24
Annexin A1 - Homo sapiens (Human) [P04083] 24
Annexin A2 - Homo sapiens (Human) [P07355] 24
Annexin A3 - Homo sapiens (Human) [P12429] 24
Annexin A4 - Homo sapiens (Human) [P09525] 24
Annexin A5 - Homo sapiens (Human) [P08758] 24
Annexin A6 - Homo sapiens (Human) [P08133] 24
Annexin A7 - Homo sapiens (Human) [P20073] 24
Annexin A8 - Homo sapiens (Human) [P13928] 24
Annexin A9 - Homo sapiens (Human) [O76027] 24
ATP synthase subunit alpha, mitochondrial-Homo sapiens (Human) [P25705] 27
ATP synthase subunit beta, mitochondrial-Homo sapiens (Human) [P06576] 27
Beta-2-glycoprotein 1 precursor - Homo sapiens (Human) [P02749] 24
Beta-2-microglobulin precursor [Contains: Beta-2-microglobulin form pI 5.3] - Homo sapiens
(Human) [P61769] 24
Complement C1q subcomponent subunit A precursor - Homo sapiens (Human) [P02745] 24
Complement C1q subcomponent subunit B precursor - Homo sapiens (Human) [P02746] 24
Complement C1q subcomponent subunit C precursor - Homo sapiens (Human) [P02747] 24
Calcitonin precursor [Contains: Calcitonin; Katacalcin - Homo sapiens (Human) [P01258] 24
Caspase-3 precursor - Homo sapiens (Human) [P42574] 24
Caspase-8 precursor - Homo sapiens (Human) [Q14790] 24
Catalase - Homo sapiens (Human) [P04040] 24
C-C chemokine receptor type 5-  Homo sapiens (Human) [P51681] 28, 29
C-X-C chemokine receptor type 4- Homo sapiens (Human) [P61073] 28
Citrate synthase, mitochondrial-  Homo sapiens (Human) [O75390] 30
T-cell surface glycoprotein CD4-  Homo sapiens (Human) [P01730] 28, 31, 32
Cyclin-A1 - Homo sapiens (Human) [P78396] 24
Cyclin-A2 - Homo sapiens (Human) [P20248] 24
Choriogonadotropin subunit beta precursor - Homo sapiens (Human) [P01233] 24
60 kDa heat shock protein, mitochondrial precursor - Homo sapiens (Human) [P10809] 24
Coagulation factor VIII Homo sapiens (Human) [P00451] 33, 34
Collagen alpha-1(I) chain precursor - Homo sapiens (Human) [P02452] 24
Collagen alpha-2(I) chain precursor - Homo sapiens (Human) [P08123] 24
Complement component C9 precursor [Contains: Complement component C9a; Complement
component C9b] - Homo sapiens (Human) [P02748] 24
Collagen alpha-1(X) chain precursor - Homo sapiens (Human) [Q03692] 24
Corticotropin-lipotropin precursor - Homo sapiens (Human) [P01189] 24
Corticoliberin precursor - Homo sapiens (Human) [P06850] 24
C-reactive protein precursor [Contains: C-reactive protein(1-205)] - Homo sapiens (Human) [P02741] 24
Cytotoxic T-lymphocyte protein 4 precursor - Homo sapiens (Human) [P16410] 24
Glutamate decarboxylase 1 - Homo sapiens (Human) [Q99259] 24
Glutamate decarboxylase 2 - Homo sapiens (Human) [Q05329] 24
Granulocyte-macrophage colony-stimulating factor- Homo sapiens (Human) [P04141] 35
DnaJ homolog subfamily B member 1 - Homo sapiens (Human) [P25685] 24
Endoplasmin/ gp96 homolog-  Homo sapiens (Human) [P14625] 27
Endothelin-1 precursor - Homo sapiens (Human) [P05305] 24
Endothelin-2 precursor - Homo sapiens (Human) [P20800] 24
Alpha-enolase- Homo sapiens (Human) [P06733] 27
Pro-epidermal growth factor precursor - Homo sapiens (Human) [P01133] 24
Volumen 71, Broj 4 VOJNOSANITETSKI PREGLED Strana 359
Djordjevi? Vuji?i? A, et al. Vojnosanit Pregl 2014; 71(4): 352–361.
Leukocyte elastase precursor - Homo sapiens (Human) [P08246] 24
Coagulation factor X precursor - Homo sapiens (Human) [P00742] 24
Coagulation factor VII precursor - Homo sapiens (Human) [P08709] 24
Alpha-2-HS-glycoprotein precursor - Homo sapiens (Human) [P02765] 24
Fetuin-B precursor - Homo sapiens (Human) [Q9UGM5] 24
Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A] - Homo sapiens (Human) [P02671] 24
Fibrinogen beta chain precursor [Contains: Fibrinopeptide B] - Homo sapiens (Human) [P02675] 24
Fibrinogen gamma chain precursor - Homo sapiens (Human) [P02679] 24
Fibronectin precursor - Homo sapiens (Human) [P02751] 24
Glyceraldehyde-3-phosphate dehydrogenase - Homo sapiens (Human) [P04406] 24, 27
Glyceraldehyde-3-phosphate dehydrogenase, testis-specific - Homo sapiens (Human) [O14556] 24
Gastrin precursor [Contains: Gastrin-71 - Homo sapiens (Human) [P01350] 24
Gelsolin precursor - Homo sapiens (Human) [P06396] 24
Glycoprotein hormones alpha chain precursor - Homo sapiens (Human) [P01215] 24
Glucagon precursor [Contains: Glicentin; Glicentin-related polypeptide - Homo sapiens (Human) [P01275] 24
Progonadoliberin-1 precursor - Homo sapiens (Human) [P01148] 24
Stress-70 protein, mitochondrial precursor - Homo sapiens (Human) [P38646] 24
Glutathione S-transferase A1 - Homo sapiens (Human) [P08263] 24
Glutathione S-transferase A2 - Homo sapiens (Human) [P09210] 24
Glutathione S-transferase A3 - Homo sapiens (Human) [Q16772] 24
Glutathione S-transferase A4 - Homo sapiens (Human) [O15217] 24
Glutathione S-transferase A5 - Homo sapiens (Human) [Q7RTV2] 24
Glutathione S-transferase kappa 1 - Homo sapiens (Human) [Q9Y2Q3] 24
Glutathione S-transferase Mu 1 - Homo sapiens (Human) [P09488] 24
Glutathione S-transferase Mu 2 - Homo sapiens (Human) [P28161] 24
Glutathione S-transferase Mu 3 - Homo sapiens (Human) [P21266] 24
Glutathione S-transferase Mu 4 - Homo sapiens (Human) [Q03013] 24
Glutathione S-transferase Mu 5 - Homo sapiens (Human) [P46439] 24
Glutathione transferase omega-1 - Homo sapiens (Human) [P78417] 24
Glutathione transferase omega-2 - Homo sapiens (Human) [Q9H4Y5] 24
Glutathione S-transferase P - Homo sapiens (Human) [P09211] 24
Glutathione S-transferase theta-1 - Homo sapiens (Human) [P30711] 24
Glutathione S-transferase theta-2 - Homo sapiens (Human) [P30712] 24
High affinity immunoglobulin epsilon receptor subunit alpha-  Homo sapiens (Human) [P12319] 36
Histone H2A type 2-C - Homo sapiens (Human) [Q16777] 24
Hemoglobin subunit alpha - Homo sapiens (Human) [P69905] 24
Hemoglobin subunit theta-1 - Homo sapiens (Human) [P09105] 24
Hemoglobin subunit zeta - Homo sapiens (Human) [P02008] 24
Hemoglobin subunit beta - Homo sapiens (Human) [P68871] 24
Hemoglobin subunit delta - Homo sapiens (Human) [P02042] 24
Hemoglobin subunit epsilon - Homo sapiens (Human) [P02100] 24
Hemoglobin subunit gamma-1 - Homo sapiens (Human) [P69891] 24
Hemoglobin subunit gamma-2 - Homo sapiens (Human) [P69892] 24
Hemoglobin subunit mu - Homo sapiens (Human) [Q6B0K9] 24
Sperm protamine-P1 - Homo sapiens (Human) [P04553] 24
Heat shock 70 kDa protein 1 - Homo sapiens (Human) [P08107] 24
Heat shock 70 kDa protein 4 - Homo sapiens (Human) [P34932] 24, 27
Heat shock 70 kDa protein 6 - Homo sapiens (Human) [P17066] 24
Putative heat shock 70 kDa protein 7 - Homo sapiens (Human) [P48741] 24
Heat shock cognate 71 kDa protein - Homo sapiens (Human) [P11142] 24, 27
Heat shock 70 kDa protein 14 - Homo sapiens (Human) [Q0VDF9] 24
Heat shock protein HSP 90-beta- Homo sapiens (Human) [P08238] 27
Heat shock protein beta-1 - Homo sapiens (Human) [P04792] 24
Islet amyloid polypeptide precursor - Homo sapiens (Human) [P10997] 24
Interferon gamma- Homo sapiens (Human) [P01579] 35
Interleukin-1 alpha- Homo sapiens (Human) [P01583] 35
Interleukin-10 precursor - Homo sapiens (Human) [P22301] 24
Interleukin-12 subunit alpha precursor - Homo sapiens (Human) [P29459] 24
Interleukin-12 subunit beta precursor - Homo sapiens (Human) [P29460] 24
Interleukin-15 precursor - Homo sapiens (Human) [P40933] 24
Interleukin-2 precursor - Homo sapiens (Human) [P60568] 24
Interleukin-21 precursor - Homo sapiens (Human) [Q9HBE4] 24
Interleukin-2 receptor alpha chain precursor - Homo sapiens (Human) [P01589] 24
Interleukin-2 receptor subunit beta precursor - Homo sapiens (Human) [P14784] 24
Interleukin-4 precursor - Homo sapiens (Human) [P05112] 24
Interleukin-5 precursor - Homo sapiens (Human) [P05113] 24
Interleukin-6 precursor - Homo sapiens (Human) [P05231] 24, 37
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Interleukin-8 precursor - Homo sapiens (Human) [P10145] 24
Insulin precursor [Contains: Insulin B chain; Insulin A chain] - Homo sapiens (Human) [P01308] 24
Keratin, type I cytoskeletal 18 - Homo sapiens (Human) [P05783] 24
Keratin, type II cytoskeletal 8 - Homo sapiens (Human) [P05787] 24
Laminin subunit alpha-1 precursor - Homo sapiens (Human) [P25391] 24
Laminin subunit alpha-2 precursor - Homo sapiens (Human) [P24043] 24
Laminin subunit alpha-3 precursor - Homo sapiens (Human) [Q16787] 24
Laminin subunit alpha-4 precursor - Homo sapiens (Human) [Q16363] 24
Laminin subunit alpha-5 precursor - Homo sapiens (Human) [O15230] 24
Laminin subunit beta-1 precursor - Homo sapiens (Human) [P07942] 24
Laminin subunit beta-2 precursor - Homo sapiens (Human) [P55268] 24
Laminin subunit beta-3 precursor - Homo sapiens (Human) [Q13751] 24
Laminin subunit gamma-1 precursor - Homo sapiens (Human) [P11047] 24
Laminin subunit gamma-2 precursor - Homo sapiens (Human) [Q13753] 24
Laminin subunit gamma-3 precursor - Homo sapiens (Human) [Q9Y6N6] 24
Low-density lipoprotein receptor precursor - Homo sapiens (Human) [P01130] 24
Lupus La protein- Homo sapiens (Human) [P05455] 38
Galectin-1 - Homo sapiens (Human) [P09382] 24
Galectin-3 - Homo sapiens (Human) [P17931] 24
Malate dehydrogenase, mitochondrial- Homo sapiens (Human) [P40926] 30
Melanoma-associated antigen E1 - Homo sapiens (Human) [Q9HCI5] 24
Melanoma antigen recognized by T-cells 1 - Homo sapiens (Human) [Q16655] 24
Pro-MCH-like protein 1 - Homo sapiens (Human) [Q16048] 24
Pro-MCH-like protein 2 - Homo sapiens (Human) [Q9BQD1] 24
Macrophage migration inhibitory factor - Homo sapiens (Human) [P14174] 24
Interstitial collagenase precursor - Homo sapiens (Human) [P03956] 24
72 kDa type IV collagenase precursor - Homo sapiens (Human) [P08253] 24
Stromelysin-1 precursor - Homo sapiens (Human) [P08254] 24
Matrix metalloproteinase-9 precursor - Homo sapiens (Human) [P14780] 24
Myelin-associated oligodendrocyte basic protein - Homo sapiens (Human) [Q13875] 24
Myelin-oligodendrocyte glycoprotein precursor - Homo sapiens (Human) [Q16653] 24
Mucin-1 precursor - Homo sapiens (Human) [P15941] 24
Myc proto-oncogene protein - Homo sapiens (Human) [P01106] 24
Myoglobin - Homo sapiens (Human) [P02144] 24, 39
Myelin proteolipid protein - Homo sapiens (Human) [P60201] 24
Oxytocin-neurophysin 1 precursor - Homo sapiens (Human) [P01178] 24
Neurotensin/neuromedin N precursor [Contains: Large neuromedin N - Homo sapiens (Human) [P30990] 24
Neuropeptide Y precursor [Contains: Neuropeptide Y - Homo sapiens (Human) [P01303] 24
Myeloperoxidase precursor - Homo sapiens (Human) [P05164] 24, 40
Phosphatidylinositol-glycan-specific phospholipase D precursor - Homo sapiens (Human) [P80108] 24
Phosphoglycerate mutase 1- Homo sapiens (Human) [P18669] 27
Plasminogen precursor - Homo sapiens (Human) [P00747] 24
Protein disulfide-isomerase/Prolyl 4-hydroxylase subunit beta- Homo sapiens (Human) [P07237] 27
Protein disulfide-isomerase A5- Homo sapiens (Human) [Q14554] 27
Protein disulfide-isomerase A3- Homo sapiens (Human) [P30101] 27
Proteolipid protein 2 - Homo sapiens (Human) [Q04941] 24
Prostatic acid phosphatase precursor - Homo sapiens (Human) [P15309] 24
Protamine-2 - Homo sapiens (Human) [P04554] 24, 41
Protamine-3 - Homo sapiens (Human) [Q9NNZ6] 24
Parathyroid hormone-related protein precursor - Homo sapiens (Human) [P12272] 24
Parathyroid hormone/parathyroid hormone-related peptide receptor precursor - Homo sapiens
(Human) [Q03431] 24
Parathyroid hormone precursor - Homo sapiens (Human) [P01270] 24
Serpin H1 precursor - Homo sapiens (Human) [P50454] 24
Serum amyloid A protein- Homo sapiens (Human) [P02735] 42
Sialic acid-binding Ig-like lectin 8/Siglec 8- Homo sapiens (Human) [Q9NYZ4] 43
Sialic acid-binding Ig-like lectin 9/Siglec 9- Homo sapiens (Human) [Q9Y336] 31
Small nuclear ribonucleoprotein Sm D1- Homo sapiens (Human) [P62314] 38
Small nuclear ribonucleoprotein Sm D2- Homo sapiens (Human) [P62316] 38
Small nuclear ribonucleoprotein Sm D3- Homo sapiens (Human) [P62318] 38
Somatoliberin precursor - Homo sapiens (Human) [P01286] 24
Somatostatin precursor - Homo sapiens (Human) [P61278] 24
60 kDa SS-A/Ro ribonucleoprotein- Homo sapiens (Human) [P10155] 38
Superoxide dismutase [Cu-Zn] - Homo sapiens (Human) [P00441] 24
Extracellular superoxide dismutase [Cu-Zn] precursor - Homo sapiens (Human) [P08294] 24
Superoxide dismutase [Mn], mitochondrial precursor - Homo sapiens (Human) [P04179] 24
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Spectrin alpha chain, erythrocyte - Homo sapiens (Human) [P02549] 24
Spectrin beta chain, brain 1 - Homo sapiens (Human) [Q01082] 24
Alpha-synuclein - Homo sapiens (Human) [P37840] 20, 24
Transforming growth factor beta-1 precursor - Homo sapiens (Human) [P01137] 24
Transforming growth factor beta-2 precursor - Homo sapiens (Human) [P61812] 24
Transforming growth factor beta-3 precursor - Homo sapiens (Human) [P10600] 24
Protein-glutamine gamma-glutamyltransferase K - Homo sapiens (Human) [P22735] 24
Protein-glutamine gamma-glutamyltransferase 2 - Homo sapiens (Human) [P21980] 24
Protein-glutamine gamma-glutamyltransferase E precursor - Homo sapiens (Human) [Q08188] 24
Protein-glutamine gamma-glutamyltransferase 6 - Homo sapiens (Human) [O95932] 24
Protein-glutamine gamma-glutamyltransferase 4 - Homo sapiens (Human) [P49221] 24
Protein-glutamine gamma-glutamyltransferase 5 - Homo sapiens (Human) [O43548] 24
Protein-glutamine gamma-glutamyltransferase Z - Homo sapiens (Human) [Q96PF1] 24
Prothrombin precursor - Homo sapiens (Human) [P00734] 24
Talin-1- Homo sapiens (Human) [Q9Y490] 44
Talin-2- Homo sapiens (Human) [Q9Y4G6 ] 44
Thy-1 membrane glycoprotein- Homo sapiens (Human) [P04216 ] 45
Thyroglobulin precursor - Homo sapiens (Human) [P01266] 24
Protachykinin 1 precursor - Homo sapiens (Human) [P20366] 24
Tubulin beta-4B chain/ Tubulin beta-2 chain- Homo sapiens (Human) [P68371] 27
Tumor necrosis factor precursor - Homo sapiens (Human) [P01375] 24
Tumor necrosis factor receptor superfamily member 6/Apo-1 antigen/FASLG receptor- Homo
sapiens (Human) [P25445] 46
Trafficking kinesin-binding protein 1- Homo sapiens (Human) [Q9UPV9] 27
Tropomyosin alpha-1 chain - Homo sapiens (Human) [P09493] 24
Tropomyosin beta chain - Homo sapiens (Human) [P07951] 24
Tropomyosin alpha-3 chain - Homo sapiens (Human) [P06753] 24
Tropomyosin alpha-4 chain - Homo sapiens (Human) [P67936] 24
Serotransferrin precursor - Homo sapiens (Human) [P02787] 24, 39
Lactotransferrin precursor - Homo sapiens (Human) [P02788] 24
Ubiquitin - Homo sapiens (Human) [P62988] 24
Vimentin- Homo sapiens (Human) [P08670] 27
Vinculin [P18206] 44
VIP peptides precursor [Contains: Intestinal peptide PHV-42; Intestinal peptide PHM-27 - Homo
sapiens (Human) [P01282] 24
Vitronectin precursor - Homo sapiens (Human) [P04004] 24
